- Home
- PRLD vs BIVI Comparison
PRLD vs BIVI Comparison
Compare PRLD & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- BIVI
- Stock Information
- Founded
- PRLD 2016
- BIVI 2013
- Country
- PRLD United States
- BIVI United States
- Employees
- PRLD N/A
- BIVI N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- BIVI Health Care
- Exchange
- PRLD Nasdaq
- BIVI Nasdaq
- Market Cap
- PRLD 73.7M
- BIVI 49.8M
- IPO Year
- PRLD 2020
- BIVI N/A
- Fundamental
- Price
- PRLD $1.39
- BIVI $2.25
- Analyst Decision
- PRLD Strong Buy
- BIVI Strong Buy
- Analyst Count
- PRLD 2
- BIVI 1
- Target Price
- PRLD $4.50
- BIVI $30.00
- AVG Volume (30 Days)
- PRLD 783.6K
- BIVI 1.2M
- Earning Date
- PRLD 02-13-2025
- BIVI 02-11-2025
- Dividend Yield
- PRLD N/A
- BIVI N/A
- EPS Growth
- PRLD N/A
- BIVI N/A
- EPS
- PRLD N/A
- BIVI N/A
- Revenue
- PRLD $3,000,000.00
- BIVI N/A
- Revenue This Year
- PRLD N/A
- BIVI N/A
- Revenue Next Year
- PRLD N/A
- BIVI N/A
- P/E Ratio
- PRLD N/A
- BIVI N/A
- Revenue Growth
- PRLD N/A
- BIVI N/A
- 52 Week Low
- PRLD $0.80
- BIVI $1.04
- 52 Week High
- PRLD $6.80
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- PRLD 60.84
- BIVI 42.62
- Support Level
- PRLD $1.12
- BIVI $1.90
- Resistance Level
- PRLD $1.48
- BIVI $2.24
- Average True Range (ATR)
- PRLD 0.18
- BIVI 0.21
- MACD
- PRLD 0.05
- BIVI -0.01
- Stochastic Oscillator
- PRLD 74.78
- BIVI 35.37
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.